Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment.
Saved in:
| Title: | Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment. |
|---|---|
| Authors: | Munroe ES; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan, United States of America., Grandits GA; Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, Minnesota, United States of America., Hyzy RC; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan, United States of America., Prescott HC; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.; VA Center for Clinical Management Research, Ann Arbor, Michigan, United States of America., Barrett TW; VA Portland Health Care System, and the Department of Medicine, Oregon Health & Science University, Portland, Oregon, United States of America., Dewar RL; Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Engen N; Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, Minnesota, United States of America., Goodman AL; MRC Clinical Trials Unit, University College London, London, United Kingdom.; Centre for Clinical Infection and Diagnostics Research at King's College London and Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom., Hatlen TJ; Division of HIV Medicine, Department of Medicine, Harbor-UCLA Medical Center, Torrance, California, United States of America., Highbarger H; Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Holland TL; Department of Medicine, Division of Infectious Diseases, Duke University, Durham, North Carolina, United States of America.; Duke Clinical Research Institute, Durham, North Carolina, United States of America., Hughes G; MRC Clinical Trials Unit, University College London, London, United Kingdom., Jensen TO; Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Denmark., Khan MA; Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Kalomenidis I; 1st Department of Critical Care and Pulmonary Medicine, National and Kapodistrian University of Athens, School of Medicine, Evaggelismos Hospital, Athens, Greece., Kang N; Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States of America., Laverdure S; Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory, Frederick, Maryland, United States of America., Manian P; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas, United States of America., Menon V; Department of Medicine, New York City Health and Hospitals, Bronx, New York, United States of America., Patel R; V.A. Bay Pines Health Care System, Florida, United States., Ramachandruni S; Christus Spohn Hospital, Corpus Christi, Texas, United States of America., Rehman T; Leidos Biomedical Research Inc., Frederick, Maryland, United States of America., Shaw-Saliba K; Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States of America., Røge BT; Department of Internal Medicine, Lillebælt Hospital, Kolding, Denmark., Vock DM; Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, Minnesota, United States of America., Weintrob AC; Infectious Diseases Section, Washington Veterans Affairs Medical Center, Washington, DC, United States of America., Young BE; National Centre for Infectious Diseases, Singapore., Frosch AP; Department of Medicine, Hennepin Healthcare Research Institute, University of Minnesota, Minneapolis, Minnesota, United States of America. |
| Corporate Authors: | STRIVE Network and Therapeutics for Inpatients with COVID-19 (TICO) study groups |
| Source: | PloS one [PLoS One] 2025 Jun 18; Vol. 20 (6), pp. e0325561. Date of Electronic Publication: 2025 Jun 18 (Print Publication: 2025). |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1932-6203 |
|---|---|
| DOI: | 10.1371/journal.pone.0325561 |
